H. Compounded vs. FDA-Approved Bioidentical Hormone Therapy: What is the Evidence?

20th Annual NPWH Premier Women's Healthcare Conference

1.25 CE (NCC Code 1), 1.25 Rx (NCC Code 1)

Marianne H. Hutti, PhD, WHNP-BC, FAANP

Since publication of the WHI in 2002 the use of conventional hormone therapy has dropped about 50-60%. At the same time, the use of custom compounded bio-identical hormone therapy (CBHT) has increased significantly. This session will examine the risks and benefits of CBHT versus FDA-approved BHT (FDA-BHT) and the ways in which these hormones differ from each other and from synthetic hormone therapy. In addition, we will evaluate the effectiveness of saliva testing in determining post-menopausal hormone status. Finally, position statements from 7 professional organizations regarding the use of CBHT will be reviewed.

Presentations